Virpax Pharmaceuticals (NASDAQ:VRPX) Stock Price Down 34.2% – Should You Sell?

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX)’s stock price fell 34.2% during mid-day trading on Monday . The company traded as low as $0.14 and last traded at $0.23. 175,850 shares changed hands during mid-day trading, a decline of 12% from the average session volume of 198,851 shares. The stock had previously closed at $0.35.

Virpax Pharmaceuticals Stock Down 34.2 %

The stock’s fifty day simple moving average is $4.87 and its 200-day simple moving average is $9.84.

Institutional Trading of Virpax Pharmaceuticals

An institutional investor recently bought a new position in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC acquired a new position in shares of Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned about 1.17% of Virpax Pharmaceuticals as of its most recent SEC filing. Institutional investors own 32.23% of the company’s stock.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.